US President Donald Trump wants to curb rising autism diagnoses, and has turned his sights on a popular over-the-counter (OTC) painkiller—Tylenol. On 22 September, Trump, alongside US Health and Human Services (HHS) Secretary Robert F. Kennedy Jr, announced “bold new actions to confront the nation’s autism spectrum disorder (ASD) epidemic". The administration has linked the use of Tylenol by pregnant women to an increased risk of autism in children, leading to widespread alarm and criticism globally. Medica ...

Core Insights - Supernus Pharmaceuticals is launching a new video series featuring Jay Glazer and his wife Rosie, focusing on the impact of ADHD on relationships and the role of Qelbree in managing ADHD symptoms [1][2][3] - The series aims to foster open discussions about ADHD, sharing practical strategies for symptom management and insights from both Jay and Rosie [2][3] Company Overview - Supernus Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing treatments for central nervous system (CNS) diseases, including ADHD [11][12] - The company has a diverse neuroscience portfolio that includes approved treatments for various CNS disorders, and is actively developing new potential treatments for conditions such as epilepsy and depression [12] Product Information - Qelbree (viloxazine extended-release capsules) is a non-stimulant prescription medication used to treat ADHD in individuals aged 6 years and older [5][10] - Qelbree is available in three dosages: 100 mg, 150 mg, and 200 mg capsules [10]

Company Overview - Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases [15] - The company has a diverse neuroscience portfolio that includes approved treatments for ADHD, dyskinesia in Parkinson's disease, epilepsy, migraine, and other CNS disorders [16] Product Information - Qelbree (viloxazine extended-release capsules) is a prescription medicine used to treat ADHD in adults and children aged 6 years and older [6] - Qelbree is a novel, once-a-day, non-stimulant approach for ADHD treatment and is the first non-stimulant approved for adults with ADHD in 20 years [4] - As a non-stimulant, Qelbree has no evidence of abuse or misuse and can be conveniently refilled without needing a new prescription each month [4] Campaign and Awareness - The 'Ms. Represented' campaign, in partnership with Busy Philipps, aims to empower women with ADHD to understand their symptoms and seek help [1][4] - The campaign highlights the often-misrepresented experiences of women with ADHD, focusing on the differences in symptom presentation between genders [2][3] - Increased awareness of ADHD symptoms among females is leading to more women seeking diagnosis and treatment [3] Market Insights - Studies indicate that boys are twice as likely as girls to be diagnosed with ADHD, resulting in many women remaining undiagnosed or misdiagnosed until adulthood [3] - The campaign seeks to address the disparity in ADHD diagnosis and treatment between males and females [4]